Sven D. Koch - Concepedia

Author

Sven D. Koch

CureVac (Germany)ORCID

Also Known As

Dirk G. Brockstedt, S D Koch, S Koch, S. D. Koch, S. KOCH, S. Koch, S.D. Koch, SVEN KOCH, Sven D Koch, Sven D. Koch

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

CureVac (Germany)University of Tübingen Heidelberg University Goethe University Frankfurt Amsterdam UMC Location University of Amsterdam

About

Sven D. Koch is an author at CureVac (Germany) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	997
2	Immunology	8	8	997
3	Cell Biology	1	1	88
4	Pathology	1	1	21
5	Autoimmune Disease	1	1	71

Sven D. Koch

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial Martin Alberer, Ulrike Gnad-Vogt, Henoch S. Hong, The Lancet VaccinationVaccine SafetyVaccine DevelopmentMrna RabiesImmunology	2017	517
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people Sven D. Koch, Anis Larbi, Evelyna Derhovanessian, Immunity & Ageing	2008	358
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer Alexandros Papachristofilou, M. Hipp, Ute Klinkhardt, Journal for ImmunoTherapy of Cancer	2019	213
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer Martin Sebastian, Andreas Schröder, Birgit Scheel, Cancer Immunology Immunotherapy Cancer ImmunosurveillancePhase I/iia StudyMedicineImmunologyCancer Genomics	2019	198
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer Martin Sebastian, Alexandros Papachristofilou, Martin Früh, BMC Cancer	2014	133
Deep Sequencing of Antiviral T-Cell Responses to HCMV and EBV in Humans Reveals a Stable Repertoire That Is Maintained for Many Years Paul L. Klarenbeek, Ester B. M. Remmerswaal, Ineke J. M. ten Berge, PLoS Pathogens	2012	111
Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas Sebastian Attig, Jörg Hennenlotter, Graham Pawelec, Cancer Research	2009	91
Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice. Othmar Dill, Femia Kievits, Sven D. Koch, Proceedings of the National Academy of Sciences HlaHistocompatibilityImmunogeneticsClassical ClassHla-cw3 Gene	1988	88
Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses Geertrude H. Struijk, Robert C. Minnee, Sven D. Koch, Kidney International Autoimmune DiseaseMaintenance Immunosuppressive TherapyImmunosuppressive TherapyImmunologyAutoimmunity	2010	71
Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) Arnulf Stenzl, S. Feyerabend, Isabel Syndikus, Annals of Oncology UrologyGenitourinary CancerMedicineImmunologyClinical Trials	2017	68

Page 1